Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL discusses the one-year follow-up results of KTE-X19 (brexucabtagene autoleucel) use in relapsed/refractory mantle cell lymphoma (MCL) in the Phase II ZUMA-2 trial (NCT02601313). 60 patients were treated with KTE-X19, an anti-CD19 CAR-T cell therapy, and followed up for a minimum of a year. Responses were deep and durable, with an overall response rate over 90% and almost half the participants with ongoing responses at data cutoff. Adverse effects were manageable, results in a promising benefit-risk profile. The results show that KTE-X19 in this patient population where curative options are lacking is of significant clinical benefit. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.